Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

aTyr Pharma, Inc. - Common Stock (NQ:ATYR)

1.025 -0.055 (-5.09%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 17, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about aTyr Pharma, Inc. - Common Stock

< Previous 1 2 Next >
Goldman Sachs To Rally around 9%? Here Are 10 Top Analyst Forecasts For Tuesday
 
Via Benzinga
Crude Oil Rises 1%; Manufacturing Activity in New York Falls In September
 
Via Benzinga
Which stocks are most active on Monday?
Stay updated with the latest market activity on Monday. Explore the most active stocks in today's session and stay informed about the stocks that are in the spotlight. 
Via Chartmill
12 Health Care Stocks Moving In Monday's Intraday Session
 
Via Benzinga
Why Is aTyr Stock Falling Today?
Via Stocktwits
aTyr Pharma, Inc. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights – ATYR
From DJS Law Group
Via Business Wire
ATyr Pharma Stock Sinks, Plans FDA Review After Mixed Phase 3 Results
ATyr Pharma's stock dips after Phase 3 trial of efzofitimod misses steroid reduction goal, but shows improvements in lung function and steroid withdrawal rates. 
Via Benzinga
Nasdaq Gains Over 100 Points; Tesla Shares Spike Higher
 
Via Benzinga
New Mountain Finance, Texas Instruments, Analog Devices And Other Big Stocks Moving Lower In Monday's Pre-Market Session
 
Via Benzinga
Why Check-Cap Shares Are Trading Higher By 183%; Here Are 20 Stocks Moving Premarket
 
Via Benzinga
Why Is Atyr Pharma Stock Slipping Premarket?
Investors braced for imminent Phase 3 EFZO-FIT trial results of efzofitimod, with analysts calling it a key inflection point. 
Via Stocktwits
1 Small-Cap Biotech Stock Poised for a Breakout
The next couple of weeks could reveal a great deal about this stock's prospects. 
Via The Motley Fool
Nvidia To Rally More Than 22%? Here Are 10 Top Analyst Forecasts For Friday
 
Via Benzinga
Alerus Financial Posts Better-Than-Expected Earnings, Joins Celcuity, SES AI, Abercrombie & Fitch And Other Big Stocks Moving Higher On Monday
 
Via Benzinga
Topics Artificial Intelligence
12 Health Care Stocks Moving In Wednesday's Intraday Session
 
Via Benzinga
GE Vernova Posts Better-Than-Expected Earnings, Joins Thermo Fisher Scientific, Lennox International, General Dynamics And Other Big Stocks Moving Higher On Wednesday
 
Via Benzinga
These stocks are gapping in today's session
The market is filled with gapping stocks in Wednesday's session. Let's discover which stocks are showing gap-ups and gap-downs. 
Via Chartmill
5 Biotech Stocks with Highly Anticipated Pending Results
Via Stocktwits
Topics Intellectual Property
These stocks that are showing activity before the opening bell on Friday.
As the US market prepares to open on Friday, let's get an early glimpse into the pre-market session and identify the stocks leading the pack in terms of gains and losses. 
Via Chartmill
12 Health Care Stocks Moving In Friday's Pre-Market Session
 
Via Benzinga
Wondering what's happening in today's after-hours session?
As the regular session of the US market concludes on Tuesday, let's get an insight into the after-hours session and identify the stocks leading the pack in terms of gains and losses. 
Via Chartmill
What's going on in today's after hours session
As the regular session of the US market on Thursday comes to an end, let's delve into the after-hours session and discover the top gainers and losers shaping the post-market sentiment. 
Via Chartmill
aTyr Pharma Announces Fourth Quarter and Full Year 2024 Results and Provides Corporate Update
From aTyr Pharma, Inc.
Via GlobeNewswire
Earnings Scheduled For March 13, 2025
 
Via Benzinga
Which stocks are gapping on Friday?
In today's session, there are notable price gaps in the US markets on Friday. Take a closer look at the stocks that are gap up and gap down. 
Via Chartmill
aTyr Pharma Announces Fourth Positive DSMB Review for Efzofitimod in Phase 3 EFZO-FIT™ Study in Pulmonary Sarcoidosis
No safety concerns identified by independent data and safety monitoring board (DSMB), which recommends continuation of study without any modifications. 
From aTyr Pharma, Inc.
Via GlobeNewswire
aTyr Pharma to Webcast Conference Call Reporting Fourth Quarter and Full Year End 2024 Financial Results
Management to host conference call and webcast on March 13th at 5:00 pm EDT / 2:00 pm PDT 
From aTyr Pharma, Inc.
Via GlobeNewswire
aTyr Pharma to Present at the Leerink Partners Global Healthcare Conference
From aTyr Pharma, Inc.
Via GlobeNewswire
This aTyr Pharma Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday
 
Via Benzinga
aTyr Pharma to Present Three Posters for Efzofitimod at the American Thoracic Society (ATS) 2025 International Conference
From aTyr Pharma, Inc.
Via GlobeNewswire
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.